Dalfampridine -AMPYRA™

Usual Dosing (Adults)

INDICATIONS AND USAGE
AMPYRA™ (dalfampridine) is a potassium channel blocker indicated to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed

DOSAGE AND ADMINISTRATION
Maximum recommended dose: 10 mg twice daily (approximately 12 hours apart) with or without food.

Patients should not take double or extra doses if a dose is missed. No additional benefit was demonstrated at doses greater than 10 mg twice daily and adverse events, including seizures, were more frequent at higher doses.

Tablets should only be taken whole; do not divide, crush, chew, or dissolve.

DOSAGE FORMS AND STRENGTHS
10 mg tablets

Renal Dosing

Renal impairment:

AMPYRA is contraindicated in patients with moderate or severe renal impairment. The risk of seizures in patients with mild renal impairment (CrCl 51-80 mL/min) is unknown, but AMPYRA plasma exposure in these patients may approach that seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures; estimated CrCl should be known before initiating treatment with AMPYRA.

Hemodialysis

Contraindicated. Do not use.

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.